These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35269542)

  • 61. Acetylation Disfavors Tau Phase Separation.
    Ferreon JC; Jain A; Choi KJ; Tsoi PS; MacKenzie KR; Jung SY; Ferreon AC
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734651
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hydration and Dynamics of Full-Length Tau Amyloid Fibrils Investigated by Solid-State Nuclear Magnetic Resonance.
    Dregni AJ; Duan P; Hong M
    Biochemistry; 2020 Jun; 59(24):2237-2248. PubMed ID: 32453948
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity.
    Frenkel-Pinter M; Tal S; Scherzer-Attali R; Abu-Hussien M; Alyagor I; Eisenbaum T; Gazit E; Segal D
    J Alzheimers Dis; 2016; 51(1):165-78. PubMed ID: 26836184
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance.
    Cook C; Carlomagno Y; Gendron TF; Dunmore J; Scheffel K; Stetler C; Davis M; Dickson D; Jarpe M; DeTure M; Petrucelli L
    Hum Mol Genet; 2014 Jan; 23(1):104-16. PubMed ID: 23962722
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hsp70 alters tau function and aggregation in an isoform specific manner.
    Voss K; Combs B; Patterson KR; Binder LI; Gamblin TC
    Biochemistry; 2012 Jan; 51(4):888-98. PubMed ID: 22236337
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology.
    Song L; Lu SX; Ouyang X; Melchor J; Lee J; Terracina G; Wang X; Hyde L; Hess JF; Parker EM; Zhang L
    Mol Neurodegener; 2015 Mar; 10():14. PubMed ID: 25881209
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Structure Biology of Tau and Clue for Aggregation Inhibitor Design.
    Wang D; Huang X; Yan L; Zhou L; Yan C; Wu J; Su Z; Huang Y
    Protein J; 2021 Oct; 40(5):656-668. PubMed ID: 34401998
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Conformation-based assay of tau protein aggregation.
    Fichou Y; Eschmann NA; Keller TJ; Han S
    Methods Cell Biol; 2017; 141():89-112. PubMed ID: 28882313
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model.
    Guha S; Fischer S; Johnson GVW; Nehrke K
    Mol Neurodegener; 2020 Nov; 15(1):65. PubMed ID: 33168053
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Loss of intramolecular electrostatic interactions and limited conformational ensemble may promote self-association of cis-tau peptide.
    Barman A; Hamelberg D
    Proteins; 2015 Mar; 83(3):436-44. PubMed ID: 25524218
    [TBL] [Abstract][Full Text] [Related]  

  • 71. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers.
    Yuzwa SA; Cheung AH; Okon M; McIntosh LP; Vocadlo DJ
    J Mol Biol; 2014 Apr; 426(8):1736-52. PubMed ID: 24444746
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nuclear magnetic resonance analysis of the acetylation pattern of the neuronal Tau protein.
    Kamah A; Huvent I; Cantrelle FX; Qi H; Lippens G; Landrieu I; Smet-Nocca C
    Biochemistry; 2014 May; 53(18):3020-32. PubMed ID: 24708343
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies.
    Ferreira A; Bigio EH
    Mol Med; 2011; 17(7-8):676-85. PubMed ID: 21442128
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dynamic structural determinants underlie the neurotoxicity of the N-terminal tau 26-44 peptide in Alzheimer's disease and other human tauopathies.
    Perini G; Ciasca G; Minelli E; Papi M; Palmieri V; Maulucci G; Nardini M; Latina V; Corsetti V; Florenzano F; Calissano P; De Spirito M; Amadoro G
    Int J Biol Macromol; 2019 Dec; 141():278-289. PubMed ID: 31470053
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Understanding the disrupting mechanism of the Tau aggregation motif "
    Moreno-Castillo E; Álvarez-Ginarte YM; Valdés-Tresanco ME; Montero-Cabrera LA; Moreno E; Valiente PA
    J Mol Recognit; 2020 Sep; 33(9):e2848. PubMed ID: 32227525
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Disclosing the Template-Induced Misfolding Mechanism of Tau Protein by Studying the Dissociation of the Boundary Chain from the Formed Tau Fibril Based on a Steered Molecular Dynamics Simulation.
    Liu H; Liu X; Zhou S; An X; Liu H; Yao X
    ACS Chem Neurosci; 2019 Mar; 10(3):1854-1865. PubMed ID: 30665304
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tauopathy: A common mechanism for neurodegeneration and brain aging.
    Saha P; Sen N
    Mech Ageing Dev; 2019 Mar; 178():72-79. PubMed ID: 30668956
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Remodeling of the conformational ensemble of the repeat domain of tau by an aggregation enhancer.
    Akoury E; Mukrasch MD; Biernat J; Tepper K; Ozenne V; Mandelkow E; Blackledge M; Zweckstetter M
    Protein Sci; 2016 May; 25(5):1010-20. PubMed ID: 26940799
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Suppressing Tau Aggregation and Toxicity by an Anti-Aggregant Tau Fragment.
    Pir GJ; Choudhary B; Kaniyappan S; Chandupatla RR; Mandelkow E; Mandelkow EM; Wang Y
    Mol Neurobiol; 2019 May; 56(5):3751-3767. PubMed ID: 30196394
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hsp40s play complementary roles in the prevention of tau amyloid formation.
    Irwin R; Faust O; Petrovic I; Wolf SG; Hofmann H; Rosenzweig R
    Elife; 2021 Aug; 10():. PubMed ID: 34369377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.